New combination treatment for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new combination treatment (CVL006 plus other drugs) in people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if the combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced, recurrent, or metastatic cancer that hasn't responded to at least one prior treatment.
- You can provide a tumor tissue sample (new or stored within 3 years) for PD-L1 testing.
- You are in good enough health to be up and about (ECOG 0-1), with a life expectancy of at least 3 months.
- You do not have untreated brain metastases, serious heart/lung issues, active infections, or a history of certain autoimmune diseases.
- You have not had certain prior cancer therapies (like PD-1/PD-L1 bispecific antibodies, or certain immunotherapies) and are willing to avoid live vaccines and strong drug interactions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This study tests a new drug, CVL006, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective for certain types of cancer, such as non-small cell lung cancer or tumors with high genetic mutations (MSI-H/dMMR or TMB-H).
This study tests a combination of two experimental cancer-fighting drugs (CVL006 and 9MW2821) in patients with advanced solid tumors, particularly head and neck cancer. The goal is to see if this combination can slow tumor growth and improve outcomes in patients whose cancers have not responded to standard treatments.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a new PARP inhibitor pill (CVL218) combined with other treatments for advanced solid tumors, especially in people with certain gene changes. It may be an option if you have had only one prior treatment or none.
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.